Improved Detection of Homologous Recombination Deficiency in Chinese Patients with Ovarian Cancer: a Novel Non-exonic Single-nucleotide Polymorphism-based Next-generation Sequencing Panel

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2023 Feb 28

PMID 36852736

Authors

Bing Wei

Jinxiang Zheng

Cai Jiang

He Zhang

Mingye Zhang

Taoran Cheng

Jun Li

Zhizhong Wang

Lijun Deng

Li Wang

Qingxin Xia

Jie Ma

Affiliations

Soon will be listed here.

Abstract

As homologous recombination deficiency (HRD) is a biomarker to predict the efficiency of PARP inhibitor treatment, this study developed a non-exonic single-nucleotide polymorphism (SNP)-based targeted next-generation sequencing panel and comprehensively examined it both on standard and clinical ovarian cancer tissues. The HRD scores calculated by the panel and whole-genome sequencing were consistent, with the analysis by sequenza being the most reliable. The results on clinical samples revealed that the panel performed better in HRD analysis compared with the SNP microarray. There are several distinctions between this newly developed kit and reported HRD detection panels. First, the panel covers only 52 592 SNPs, which makes it capable of detecting genomic instability. Secondly, all the SNPs are non-exonic; as a result, the panel can be used cooperatively with any exon panel. Thirdly, all the SNPs selected have a high minor allele frequency in Chinese people, making it a better choice for HRD detection in Chinese patients. In summary, this panel shows promise as a clinical application to guide PARP inhibitors or platinum drugs used in the treatment of ovarian and other cancers.

References

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

Stover E, Fuh K, Konstantinopoulos P, Matulonis U, Liu J . Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020; 159(3):887-898. DOI: 10.1016/j.ygyno.2020.09.029. View

Sztupinszki Z, Diossy M, Krzystanek M, Reiniger L, Csabai I, Favero F . Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. NPJ Breast Cancer. 2018; 4:16. PMC: 6028448. DOI: 10.1038/s41523-018-0066-6. View

Nakashima S, Kobayashi S, Nagano H, Tomokuni A, Tomimaru Y, Asaoka T . BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer. Cancer Sci. 2015; 106(5):584-91. PMC: 4452159. DOI: 10.1111/cas.12652. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R . Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25):2416-2428. DOI: 10.1056/NEJMoa1911361. View

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Zhang Y, Shi X, Zhang J, Chen X, Zhang P, Liu A . A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients. Sci Rep. 2021; 11(1):387. PMC: 7801677. DOI: 10.1038/s41598-020-79694-0. View

10.

Liu Q, Ghosh P, Magpayo N, Testa M, Tang S, Gheorghiu L . Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. Int J Radiat Oncol Biol Phys. 2015; 91(5):1081-9. DOI: 10.1016/j.ijrobp.2014.12.046. View

11.

Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E . Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review. Diagnostics (Basel). 2019; 9(3). PMC: 6787707. DOI: 10.3390/diagnostics9030087. View

12.

Lotan T, Kaur H, Salles D, Murali S, Schaeffer E, Lanchbury J . Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod Pathol. 2021; 34(6):1185-1193. PMC: 8154637. DOI: 10.1038/s41379-020-00731-4. View

13.

Dai C, Li J, Chen P, Jiang H, Wu M, Chen Y . RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells. J Biomed Sci. 2015; 22:77. PMC: 4575453. DOI: 10.1186/s12929-015-0185-4. View

14.

Li X, Heyer W . Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008; 18(1):99-113. PMC: 3087377. DOI: 10.1038/cr.2008.1. View

15.

Lowe K, Chia V, Taylor A, OMalley C, Kelsh M, Mohamed M . An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013; 130(1):107-14. DOI: 10.1016/j.ygyno.2013.03.026. View

16.

Marquard A, Eklund A, Joshi T, Krzystanek M, Favero F, Wang Z . Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015; 3:9. PMC: 4443545. DOI: 10.1186/s40364-015-0033-4. View

17.

Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T . Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012; 72(21):5454-62. DOI: 10.1158/0008-5472.CAN-12-1470. View

18.

Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N . Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 2020; 10(1):2757. PMC: 7026096. DOI: 10.1038/s41598-020-59671-3. View

19.

Telli M, Timms K, Reid J, Hennessy B, Mills G, Jensen K . Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016; 22(15):3764-73. PMC: 6773427. DOI: 10.1158/1078-0432.CCR-15-2477. View

20.

Heeke A, Pishvaian M, Lynce F, Xiu J, Brody J, Chen W . Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis Oncol. 2018; 2018. PMC: 6139373. DOI: 10.1200/PO.17.00286. View